Europska Unija - hrvatski - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - multipli mijelom - antineoplastična sredstva - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - psorijaza - imunosupresivi - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Europska Unija - hrvatski - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - multipli mijelom - antineoplastična sredstva - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

janssen-cilag international nv - danmavir - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Europska Unija - hrvatski - EMA (European Medicines Agency)

janssen-cilag international n.v.    - ponesimod - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Europska Unija - hrvatski - EMA (European Medicines Agency)

biofrontera bioscience gmbh - 5-aminolevulinska kiselina hidroklorid - keratosis, actinic; carcinoma, basal cell - antineoplastična sredstva - liječenje актинического кератоза blage i umjerene težine na licu i vlasištu (olsen klasa 1 i 2; vidi odjeljak 5. 1) i polje cancerization kod odraslih. tretman površina i/ili узелковый karcinom bazalnih stanica neprikladne za kirurško liječenje zbog mogućeg liječenja bolesti i/ili nezadovoljavajuće kozmetički rezultat kod odraslih.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

pharmaswiss Česká republika s.r.o., jankovcova 1569/2c, prag, Češka - azathioprinum - filmom obložena tableta - 25 mg - urbroj: jedna filmom obložena tableta sadrži 25 mg azatioprina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

pharmaswiss Česká republika s.r.o., jankovcova 1569/2c, prag, Češka - azathioprinum - filmom obložena tableta - 50 mg - urbroj: jedna filmom obložena tableta sadrži 50 mg azatioprina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - бортезомиб - prašak za otopinu za injekciju - 3,5 mg - urbroj: svaka bočica sadrži 3,5 mg bortezomiba (u obliku estera boronatne kiseline i manitola)

Europska Unija - hrvatski - EMA (European Medicines Agency)

3m health care limited - rivastigmin - alzheimerova bolest - psychoanaleptics, , Антихолинэстеразных - simptomatsko liječenje blage do umjereno teške alzheimerove demencije.